P&G ready to assess Teva staffing; Congress to devote fall to healthcare, FDA;

> Watch out, Teva: Now that Procter & Gamble has bought the generics-maker and sold its Pringles business, it's time for HQ to take a look at staffing levels. Story

> The House Energy and Commerce Committee's Health panel will spend the fall focused on healthcare reform regulations and preparing for a major FDA bill. Story

> Dendreon ($DNDN) has canceled its $8.3-million contract with GlaxoSmithKline ($GSK) for high-volume manufacture of the lackluster cancer vaccine Provenge, but may still be on the hook for a monthly fee of $2 million for September and October for breaching a 60-day notice requirement. Story

> Roche has unveiled a desktop continuous-random-access analyzer of chemical and biochemical parameters in aqueous solutions, intended for metabolite screening and substrate analysis. Roche release

> Big 3 drug distributor AmerisourceBergen ($ABC) has acquired IntrinsiQ, an informatics solution provider that targets community oncologists to help them make treatment decisions for their patients. Release

> Lonza Group and Shanghai Fosun Pharmaceutical Group plan to invest $15.7 million to create a joint venture in Pudong Zhangjiang High-Tech Industry Zone. Item

> Xcelience, a leader in early drug development, has expanded its equipment arsenal for clinical trial supply manufacturing and packaging. Xcelience release

Suggested Articles

South Korea’s Celltrion, which has a massive biologics site in Songdo, has decided it is time to build some operations in China.

WuXi Biologics is taking control of a Bayer plant in Germany and agreed it could serve as a backup facility for supply of hemophilia drug Kovaltry.

A Chinese OTC drugmaker gets the distinction of ringing in the new year as the first company to be slapped with an FDA warning letter.